Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633256 · ClinicalTrials.gov registry record · NA
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00633256 is a NA study that has completed, run by Yale University. The registered enrollment target is 20 participants.
The verdict
NCT00633256, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
A total of 20 subjects will participate in this four week, between groups, double-blind, placebo controlled study. Subjects will participate in two experimental sessions separated by approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or placebo combined with cue exposure. Several physiological and subjective outcome measures (e.g., heart rate, blood pressure, galvanic skin response) will be obtained during the sessions. Experimental sessions will last approximately 4.5 hours with follow-up sessions lasting approximately thirty minutes. Our aims are: 1. To examine the effect of cycloserine vs. placebo on extinction of smoking cue reactivity in overnight abstinent smokers. Reactivity to smoking cues will be captured with self-report smoking urges and physiological measures (heart rate, blood pressure, and skin conductance). We hypothesize that cycloserine, relative to placebo, will facilitate extinction of smoking cue reactivity. 2. To examine the effect of cycloserine vs. placebo when combined with two 4.5 hour laboratory cue exposure training sessions, on smoking behavior in smokers. Smoking behavior will be measured with self-report smoking and saliva cotinine levels. 3. To examine the effect of cycloserine vs. placebo on memory performance in nicotine dependent smokers. Memory performance will be measured with verbal learning, recognition and recall tasks. 4\) To examine the safety and tolerability of cycloserine treatment in smokers. We hypothesize that cycloserine will be well tolerated by smokers.
Interventions
- DRUG Placebo
- DRUG Cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633256
The ClinicalTrials.gov registry entry for NCT00633256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00633256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633256 about?
NCT00633256 is a clinical study titled "The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers". A total of 20 subjects will participate in this four week, between groups, double-blind, placebo controlled study. Subjects will participate in two experimental sessions separated by approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or placebo combined with cue ...
What is the current status of trial NCT00633256?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2006-12. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00633256?
The interventions under investigation include: Placebo (DRUG), Cycloserine (DRUG).
Who is sponsoring clinical trial NCT00633256?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.